Compare Neurocrine Biosciences Inc (NBIX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Noble Corporation plc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Noble Corporation plc trades at $42.53 (market cap $6.48B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.7× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NE | |
|---|---|---|
Market Cap | $17.40B | $6.48B |
Sector | Health | Technology |
52-Week High | $180.55 | $54.37 |
52-Week Low | $123.10 | $25.70 |
Enterprise Value | $16.49B | $7.73B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Noble Corporation (NE) trades at $40.60, down 2.17% on the day, with a neutral technical signal. The company reported mixed Q1 2026 earnings, beating expectations, but missed in the prior two quarters. Recent news highlights new offshore drilling contracts, including a $136.2 million Brunei deal, and the upcoming Q2 2026 earnings report on July 27, 2026. Positive cash flow and a dividend payment of $0.50 per share in June 2026 support shareholder returns.
The outlook is cautiously optimistic, supported by new contracts and a consensus price target of $49.75, implying potential upside. Risks include execution on earnings expectations and offshore drilling market volatility. Analyst sentiment is mixed, with 31% Buy ratings, but the stock's current price is near the low end of the target range, suggesting a balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
